The UK is to bring in vaccination programs to protect babies and young people against the meningococcal bacterium, serogroup B.
Bexsero, the meningococcal serogroup B vaccine from UK pharma major GlaxoSmithKline (LSE: GSK), will be given to babies from two months of age with a second dose at four months and a booster at 12 months. This will make it the first national meningitis B program in the world.
The implementation of this scheme has been delayed due to cost disputes, and although pricing details have not been disclosed, GSK said that the agreement gave “fair value for the NHS and allows a reasonable return” for the company. The agreement between the government and GSK was reached in March following the Joint Committee on Vaccination and Immunisation’s (JCVI) guidance recommending the addition of Bexsero to the immunization program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze